The next ELIXIR Innovation event will be focused on Rare Diseases and Personalised Medicine. Have a look at the programme of this lunch-to-lunch event in which you will be immersed in a world of data-driven innovation, illustrated by innovative companies and ELIXIR’s open data resources and services. This is accomplished by a mix of high-level keynote speakers and interactive sessions in which you can discuss and interact with other companies and ELIXIR partners. This is a free event but registration is mandatory.
What is on the programme?
A large number of experts will take the floor. An overview of the line-up:
- Interactive sessions to present data resources in rare disease and personalised medicine research and innovative companies already using those resources.
- Resources available through ELIXIR: Orphanet (Marc Hanauer), RD Connect (TBA), European Genome Phenome Archive and ELIXIR personalised medicine plans (EGA) (Susheel Varma), ELIXIR Rare Disease use case (Sergi Beltran)
- Companies: Ontoforce (Filip Pattyn), Sanofi-Genzyme (TBA)
- “Meet the expert session” where several experts will discuss with attendees in 10 minutes slots FAIR data management, public private partnerships, hands on demos of Orphanet and RD connect, and funding opportunities.
- We will also organise a “Flash-talk” session” 5 minute talks for companies to present their activities.
This event is aimed at companies active in Rare Diseases and Personalised Medicine, software companies working with data in life-sciences and all research institutes active in the field of data and health.
Meet and greet Apart from coffee breaks and lunches, you can also attend the networking reception and walking dinner on Wednesday November 14th.
Testimonials (of companies attending previous ELIXIR Innovation events)
With Intomics we derive value from integrating various public bioinformatics resources and providing commercial services on top. The ELIXIR Innovation and SME Forum (Oslo, 2016) gave us the opportunity to learn more about these public resources and to interact directly with those running them so they understand our needs better. Annette Vibeke Uldall, Intomics
I made good connections, and expect to start several new translational bioinformatics projects as the result of the meeting. John Castle, Senior Director, Bioinformatics, 4-Antibody AG & Agenus
- Jean Francoise Deleuze (Scientific Director of the Fondation Jean Dausset-CEPH / Director of the Centre National de Génotypage (CNG-IG-CEA)
- Daria Julkowska (Programme coordinator eRARE)
- William Saurin (Dassault Systèmes)